肺动脉高压治疗药物研究进展被引量：2

Research Development of Therapeutic Drug in Pulmonary Arterial Hypertension

下载PDF

导出

摘要肺动脉高压是以肺动脉增生、重构为特征并导致肺循环阻力进行性增高、右心室后负荷增加、最终出现右心功能衰竭的一种严重疾病。经过多年研究,人类在肺动脉高压药物治疗方面已取得长足进展,肺动脉高压患者生存率有了一定的提高,然而绝大多数肺动脉高压患者长期预后欠佳,治疗药物的研发仍为临床亟需。

作者肖云彬黄希勇

机构地区湖南省儿童医院

出处《儿科药学杂志》 CAS 2013年第1期60-64,共5页 Journal of Pediatric Pharmacy

关键词肺动脉高压治疗药物右心功能衰竭肺循环阻力心室后负荷长期预后进行性治疗方

分类号 R544.16 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献34

1Barst RJ,McGoon M,McLaughlin V. Beraprost therapy for pulmonary arterial hypertension[J].Journal of the American College of Cardiology,2003,(12):2119-2125.
2Mubarak KK. A review of prostaglanflin analogs in the management of patients with pulmonary arterial hypertension[J].Respiratory Medicine,2010,(01):9-21.
3Simonneau G,Barst RJ,Galie N. Continuous subcutaneous infusion of treprostinil,a prostacyclin analogue,in patients with pulmonary arterial hypertension:a double-blind,randomized,placebo-controlled trial[J].American Journal of Respiratory and Critical Care Medicine,2002,(06):800-804.
4Barst R J,Galie N,Naeije R. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil[J].European Respiratory Journal,2006,(06):1195-1203.
5Moreno-Vinasco L,Garcia JG. Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension[J].Advances in Experimental Medicine and Biology,2010.419-434.
6The U.S.National Institutes of Health. ClinicalTrials.gov.Sorafenib study:dosing in patients with pulmonary arterial hypertension (PAH)[EB/OL].http://clinicaltrials.gov/ct2/show/NCT00452218? term=NCT00452218&rank=1,.
7Pritchard KA Jr,Shi Y,Konduri GG. Tetrahydrobiopterin in pulmonary hypertension:pulmonary hypertension in guanosine triphosphate-cyclohydrolaae.-deficient mice[J].Circulation,2005,(16):2022-2024.
8Tapson VF,Torres F,Kermeen F. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Backgrround Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study):A Randomized Controlled Trial[J].Chest,2012.
9Kuwano K,Hashino A,Asaki T. 2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304),an orally available and long-acting prostacyclin receptor agonist prodrug[J].Journal of Pharmacology and Experimental Therapeutics,2007,(03):1181-1188.
10Sakao S,Tatsumi K. Vascular remodeling in pulmonary arterial hypertension:multiple cancer-like pathways and possible treatment modalities[J].International Journal of Cardiology,2011,(01):4-12.